Advanced Hybrid Stent System for Chronic Venous Disease Treatment

A next-generation hybrid stent system for treating chronic venous disease, featuring a braided stent portion and a zigzag wire stent portion, with enhanced biocompatibility, adaptability, and therapeutic capabilities.

The original Integrated Z and Wallstent patent has limitations in terms of stent material, structure, and deployment. The new inventive concept addresses these limitations by introducing a hybrid stent system that combines the benefits of braided and zigzag wire stents, providing improved flexibility, adaptability, and therapeutic capabilities for treating chronic venous disease.

The advanced hybrid stent system consists of a braided stent portion and a zigzag wire stent portion, attached via a nanomaterial-based adhesive. The zigzag wire stent portion can be coated with a bioactive material that promotes endothelialization, and the braided stent portion can be made of a shape-memory alloy that adapts to the patient's anatomy. The hybrid stent system can be deployed using a minimally invasive procedure and can be treated with therapeutic agents to enhance its effectiveness. The 3D printing process enables the creation of customized stent systems with complex geometries and structures.

The new claims introduce a paradigm shift in stent technology by combining braided and zigzag wire stents, utilizing nanomaterial-based adhesives, shape-memory alloys, and bioactive coatings. These advancements provide a significant improvement over the original patent, offering enhanced biocompatibility, adaptability, and therapeutic capabilities.

Alternative embodiments of the hybrid stent system could include varying the material composition, structure, and geometry of the braided and zigzag wire stent portions. Additionally, the adhesive material and coating technologies could be modified to enhance the stent system's performance and biocompatibility.

The advanced hybrid stent system has significant commercial potential in the medical device industry, particularly in the treatment of chronic venous disease. The target market includes hospitals, clinics, and medical research institutions, with potential applications in other vascular diseases and conditions.